Jilin Aodong Pharmaceutical Group000623.SZValuation Analysis

As of Oct 19, 2026, Jilin Aodong Pharmaceutical Group (000623.SZ) trades at a P/E of 6.46x, P/B of 0.64x, P/S of 9.92x, and a dividend yield of 2.87%.
Longitudinal percentile comparison: P/E sits at the 0th percentile over the trailing 10Y window (vs. 1st percentile over 3Y); P/B sits at the 5th percentile over the trailing 10Y window (vs. 15th percentile over 3Y); P/S sits at the 89th percentile over the trailing 10Y window (vs. 71st percentile over 3Y).
Cross-sectional valuation: its P/E ranks at the 10th percentile within its industry and the 1st percentile across the broader market.
Shareholder return highlight: Total Shareholder Yield is 3.45%, ranking at the 90th percentile over the trailing 20Y window.
The P/E and P/B long-window percentiles differ by only 4.7 points, pointing to a consistent valuation read across both metrics. Relative to the broader market, its P/E shows a deeper discount than it does against industry peers. Breaking down the total shareholder yield: 2.87% comes from cash dividends, with an implied ~0.59% from buybacks — a fairly balanced mix of both channels. Jilin Aodong Pharmaceutical Group operates in the Non Bank Finance sector. Data refreshes weekly and is for reference only, not investment advice.